BCAL Diagnostics Limited (AU:BDX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BCAL Diagnostics Limited reports successful completion of early stages in the SENSIBLE study, refining the lipid panel for their innovative blood-based breast cancer test, BREASTEST®, aimed at enhancing early detection. The company has strengthened its leadership with the appointment of Shane Ryan as CEO, who brings significant commercial launch experience, and has made progress in securing intellectual property rights with additional patents and trademarks. With $3.3 million in cash reserves, BCAL is accelerating sample collection across Australia and forging key opinion leader partnerships for the upcoming commercial launch of BREASTEST®.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.